SEARCH:   Advanced

Blood, 15 June 2007, Vol. 109, No. 12, pp. 5151-5156. Prepublished online as a Blood First Edition Paper on March 9, 2007; DOI 10.1182/blood-2006-09-046144. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-09-046144v1 109/12/5151    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Harousseau, J.-L. Articles by Stone, R. Search for Related Content PubMed PubMed Citation Articles by Harousseau, J.-L. Articles by Stone, R. Related Collections Neoplasia Signal Transduction Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia Jean-Luc Harousseau1, Jeffrey E. Lancet2, Josy Reiffers3, Bob Lowenberg4, Xavier Thomas5, Francoise Huguet6, Pierre Fenaux7, Steven Zhang8, Wayne Rackoff8, Peter De Porre8, Richard Stone9, for the Farnesyltransferase Inhibition Global Human Trials (FIGHT) Acute Myeloid Leukemia Study Group 1 From the Service d'Hématologie, Hôtel Dieu, Nantes, France; 2 H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa; 3 Service des Maladies du Sang, Hôpital du Haut Leveque, Pessac, France; 4 Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; 5 Service des Maladies du Sang, Hôpital Edouard Herriot, Lyon, France; 6 Service d'Hématologie, Chu Purpan, Toulouse Cedex, France; 7 Hématologie, Avicenne Hôpital, Paris, France; 8 Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ; and 9 Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA This phase 2 study evaluated the efficacy and safety of the oral farnesyltransferase inhibitor tipifarnib in adults with refractory or relapsed acute myeloid leukemia (AML). Patients (n = 252) received tipifarnib 600 mg twice a day for 21 days in 28-day cycles. Median age was 62 years; 99 (39%) patients were 65 years or older. Eleven (4%) of 252 patients achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp; 9 CR and 2 CRp). Nineteen patients (8%), including those who achieved CR/CRp, achieved a reduction in bone marrow blasts to less than 5% blasts. Bone marrow blasts were reduced more than 50% in an additional 8 patients (total = 27; 11%). Median survival was 369 days for patients who achieved CR/CRp. Myelosuppression was the most common adverse event. The most common nonhematologic toxicities were fever, nausea, and hypokalemia. Single-agent treatment with tipifarnib induced durable CR/CRp, which was associated with prolonged survival, in some patients with refractory or relapsed AML. The response rate observed in this heavily pretreated group of patients suggests the requirement to enhance the response rate either by combining tipifarnib with other active agents or determining factors that are predictive of response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. M. Stone Genetically Defined Prognostic Factors and Novel Therapeutics for AML ASCO Educational Book, January 1, 2008; 2008(1): 280 - 284. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020